Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMB-1018972 drug-drug interaction study with repaglinide, midazolam, paroxetine, and fluvoxamine in healthy subjects
NL-OMON48361Active, not recruiting
- Sponsor
- Imbria Pharmaceuticals
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ninerafaxstat, repaglinide, midazolam, paroxetine and fluvoxamine in coronary arteriosclerosis and angina pectoris (3 arms), sponsored by Imbria Pharmaceuticals. Primary endpoints: Effect of IMB-1018972 on repaglinide and midazolam pharmacokinetics, Effect of paroxetine on IMB-1018972 pharmacokinetics and 1 more. Started Aug 2019; status: active, not recruiting.
02
Drugs
ninerafaxstatrepaglinidemidazolamparoxetinefluvoxamine
03
Conditions
coronary arteriosclerosisangina pectoris
Beyond the preview
Go deeper on NL-OMON48361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48361.